NEW YORK (GenomeWeb) – Bio-Rad Laboratories has announced a partnership with Genetic Analysis, an Oslo, Norway-based clinical diagnostics firm focusing on the microbiome.

Under the terms of the agreement, Bio-Rad will make an equity investment in Genetic Analysis. In return, it will receive commercialization rights in certain undisclosed territories for Genetic Analysis' CE-marked GA-map technology to detect microbial imbalances, also known as gut dysbiosis, the firms said in a statement.

Financial and other details were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.